Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Mol Cancer Ther. 2019 Nov;18(11):1909–1915. doi: 10.1158/1535-7163.MCT-19-0214

Figure 1.

Figure 1

Resistant mechanisms of EGFR targeted therapy. The following molecular activities will result in bypassing EGFR blockade: (A) Activation mutations or amplification of EGFR downstream signaling effectors; (B) Overexpression of MET proto-oncogene and expression of EGFR variant III; (C) Hetero-dimerization between EGFR family members; and (D) Activation of TGF-beta IL-6 axis